{"id":"https://openalex.org/W112797146","doi":null,"title":"[Cost-effect estimation of dopamine agonist (mirapex) application in patients with Parkinson's disease].","display_name":"[Cost-effect estimation of dopamine agonist (mirapex) application in patients with Parkinson's disease].","publication_year":2004,"publication_date":"2004-01-01","ids":{"openalex":"https://openalex.org/W112797146","mag":"112797146","pmid":"https://pubmed.ncbi.nlm.nih.gov/15553375"},"language":"ru","primary_location":{"id":"pmid:15553375","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15553375","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","raw_type":"Clinical Trial"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083821808","display_name":"A B Gekht","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A B Gekht","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Iu B Belousov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Iu B Belousov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025990606","display_name":"Chikina Es","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E S Chikina","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008849861","display_name":"Serkin Gv","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G V Serkin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"D Iu Belousov","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D Iu Belousov","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5080048614","display_name":"E I Gusev","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E I Gusev","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2119,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.55679742,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"104","issue":"10","first_page":"26","last_page":"33"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.8769999742507935,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.8769999742507935,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.11270000040531158,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dopamine-agonists","display_name":"dopamine agonists","score":0.9089999794960022},{"id":"https://openalex.org/keywords/pramipexole","display_name":"pramipexole","score":0.8429999947547913},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8389999866485596},{"id":"https://openalex.org/keywords/levodopa","display_name":"levodopa","score":0.8299999833106995},{"id":"https://openalex.org/keywords/unified-parkinson-s-disease-rating-scale","display_name":"Unified Parkinson's Disease Rating Scale","score":0.8840000033378601},{"id":"https://openalex.org/keywords/pdq-39","display_name":"PDQ-39","score":0.9919999837875366},{"id":"https://openalex.org/keywords/treatment-costs","display_name":"treatment costs","score":0.5640000104904175}],"concepts":[{"id":"https://openalex.org/C2780304432","wikidata":"https://www.wikidata.org/wiki/Q300989","display_name":"Levodopa","level":4,"score":0.9053223133087158},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8404267430305481},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.7236166000366211},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.6765633225440979},{"id":"https://openalex.org/C2778258207","wikidata":"https://www.wikidata.org/wiki/Q600203","display_name":"Dopamine agonist","level":4,"score":0.6409032344818115},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5593685507774353},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5483700037002563},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.34409984946250916},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.28980058431625366},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:15553375","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15553375","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","raw_type":"Clinical Trial"},{"id":"mag:112797146","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15553375","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1983197953","https://openalex.org/W2165389155","https://openalex.org/W2099262625","https://openalex.org/W2144502967","https://openalex.org/W3159111995","https://openalex.org/W4213101420","https://openalex.org/W1589312118","https://openalex.org/W2062629922","https://openalex.org/W4246483326","https://openalex.org/W2117713654"],"abstract_inverted_index":{"Parkinson's":[0,61],"disease":[1],"is":[2],"a":[3,7,92],"neurodegenerative":[4],"disorder":[5],"with":[6,60,66,72,83,98],"growing":[8],"social":[9],"significance.":[10],"Currently,":[11],"dopamine":[12,26,93],"agonists":[13,27],"are":[14],"considered":[15],"as":[16,91,107],"first-line":[17],"medication":[18],"used":[19],"before":[20,52],"levodopa":[21,67,99],"treatment.":[22],"High":[23],"cost":[24,34,75],"of":[25,38,44,89,111],"makes":[28],"it":[29],"necessary":[30],"to":[31,101],"estimate":[32],"their":[33],"efficacy":[35,43],"by":[36,47],"means":[37],"pharmacoeconomical":[39],"studies.":[40],"We":[41],"studied":[42],"mirapex":[45,90],"evaluated":[46],"UPDRS":[48],"and":[49,53,68],"PDQ-39":[50],"scores":[51],"after":[54],"1-year":[55],"treatment":[56],"in":[57],"44":[58],"patients":[59,64,70,81,96],"disease:":[62],"18":[63],"non-pretreated":[65],"26":[69],"pretreated":[71],"levodopa.":[73],"Treatment":[74],"was":[76],"estimated":[77],"separately":[78],"for":[79,95],"two":[80],"groups":[82],"subsequent":[84],"cost-effectiveness":[85],"analysis.":[86],"Early":[87],"use":[88],"agonist":[94],"non-treated":[97],"seems":[100],"be":[102],"beneficial":[103],"from":[104,108],"clinical":[105],"well":[106],"pharmacieconomical":[109],"points":[110],"view.":[112]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}